고콜레스테롤혈증 시장 : 유형별, 진단 및 치료별, 환자별, 최종사용자별, 지역별(2025-2033년)

The global hypercholesterolemia market size reached USD 20.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 64.0 Billion by 2033, exhibiting a growth rate (CAGR) of 13.05% during 2025-2033. Rising health consciousness, increasing geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market growth.

Hypercholesterolemia is a lipid disorder known for an excess of low-density lipoprotein (LDL) in the blood. Some of the common conditions that lead to hypercholesterolemia are diabetes, polycystic ovary syndrome, underactive thyroid gland, and kidney diseases. It is a long-term condition, and chest pain, shortness of breath, extreme fatigue, and muscle weakness are some of the most common symptoms. Hypercholesterolemia is a serious life-threatening ailment wherein drugs are used to decrease the level of bad cholesterol in the blood while reducing the liver's production of harmful cholesterol. These drugs help stabilize the plaques on blood vessel walls and reduce the risk of certain blood clots. They also reduce the risk of a heart attack or stroke and dysfunction in the blood vessels.

Hypercholesterolemia Market Trends:

The growing prevalence of hypercholesterolemia due to the rising unhealthy lifestyle among the masses is one of the key factors driving the market growth. In line with this, the increasing geriatric population that is susceptible to cardiovascular disorders (CVDs) and various other chronic diseases, such as diabetes, kidney complications, and thyroid problems, is favoring the market growth. Moreover, the rising health consciousness and the increasing awareness regarding the available treatment alternatives for hypercholesterolemia are acting as other growth-inducing factors. Along with this, the introduction of various drugs and therapies to achieve near-normal lipid profiles in hypercholesterolemia patients and reduce the risk of CVDs occurrence in patients is providing a considerable boost to the market growth. Apart from this, the development of novel drug classes with enhanced efficacy and safety profile is providing an impetus to the market growth. Additionally, the launch of various combination therapies with other cholesterol-diminishing compounds to treat hypercholesterolemia is positively influencing the market growth. Besides this, the widespread adoption of statins due to their several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation is facilitating the market growth. Other factors, including overall improvements in the healthcare infrastructure, extensive research, and development (R&D) activities for developing novel drugs, and the increasing number of familial hypercholesterolemia patients, are anticipated to drive the market growth.

Key Market Segmentation:

Type Insights:

• Type 1
• Type 2A
• Type 2B
• Type 3
• Type 4
• Type 5
• Others

Diagnosis and Treatment Insights:

• Diagnosis
• Cholesterol Test
• Genetic Testing
• Treatment
• Statins
• Niacin
• Bile Acid Resins
• Fibric Acid Derivatives
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• Others

Patient Insights:

• Pediatric
• Adults
• Geriatric

End User Insights:

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hypercholesterolemia. Some of the factors driving the North America hypercholesterolemia market included its growing prevalence of hypercholesterolemia, increasing geriatric population, and rising unhealthy lifestyle among the masses.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global hypercholesterolemia market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., Dr. Reddy's Laboratories, Lupin Limited, Novartis AG, Regeneron Pharmaceuticals, Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global hypercholesterolemia market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global hypercholesterolemia market?
• What are the key regional markets?
• Which countries represent the most attractive hypercholesterolemia markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the diagnosis and treatment?
• What is the breakup of the market based on patient?
• What is the breakup of the market based on the end user?
• What is the competitive structure of the global hypercholesterolemia market?
• Who are the key players/companies in the global hypercholesterolemia market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hypercholesterolemia Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Type 1
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Type 2A
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Type 2B
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Type 3
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Type 4
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Type 5
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

• 7.1 Diagnosis
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Cholesterol Test
    • 7.1.2.2 Genetic Testing
  • 7.1.3 Market Forecast
• 7.2 Treatment
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Statins
    • 7.2.2.2 Niacin
    • 7.2.2.3 Bile Acid Resins
    • 7.2.2.4 Fibric Acid Derivatives
    • 7.2.2.5 Cholesterol Absorption Inhibitors
    • 7.2.2.6 PCSK9 Inhibitors
    • 7.2.2.7 Others
  • 7.2.3 Market Forecast

8 Market Breakup by Patient

• 8.1 Pediatric
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Adults
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Geriatric
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Specialty Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Home Healthcare
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Amgen Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Dr. Reddy's Laboratories
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Lupin Limited
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Novartis AG
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Regeneron Pharmaceuticals, Inc
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report